<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972621</url>
  </required_header>
  <id_info>
    <org_study_id>VSCO-106-DISP</org_study_id>
    <nct_id>NCT00972621</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of a New Viscoelastic for Cataract Surgery</brief_title>
  <official_title>Clinical Evaluation of a New Viscoelastic for Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of a new opthalmic
      viscoelastic material for the use in cataract surgery. The new viscoelastic will be compared
      to a currently marketed viscoelastic material.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Intraocular Pressure Spikes 30 mm Hg or Greater Postoperatively</measure>
    <time_frame>3 months postoperative</time_frame>
    <description>Cumulative rate of Intraoperative Pressure (IOP) spikes 30 mm Hg (millimeters of mercury) or greater measured postoperatively through three months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Mean Endothelial Cell Count</measure>
    <time_frame>3 months postoperative</time_frame>
    <description>mean endothelial cell count (measured by Konan specular microscope) at 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Vitrax II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational dispersive viscoelastic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viscoat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed control dispersive viscoelastic</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitrax II</intervention_name>
    <description>Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.</description>
    <arm_group_label>Vitrax II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Viscoat</intervention_name>
    <description>Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..</description>
    <arm_group_label>Viscoat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy eye with no pathology other than the presence of cataract

          -  Visual potential of 20/40 or better

        Exclusion Criteria:

          -  Taking any medications that affect vision, intraocular pressure or ease of cataract
             surgery (e.g. flomax, glaucoma medications, etc.)

          -  Known intraocular pressure increases from steroid treatment

          -  Low endothelial cell count
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AMO Clinical Research Call Center for Trial Locations</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2009</study_first_posted>
  <results_first_submitted>January 18, 2012</results_first_submitted>
  <results_first_submitted_qc>January 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2012</results_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the general cataract populations from 11 ophthalmic practices between September 2009 and July 2010.</recruitment_details>
      <pre_assignment_details>Enrolled participants who did not meet the inclusion/exclusion criteria as detailed in the protocol were excluded from the trial prior to assignment to study group. Randomization assigned199 Vitrax II subjects and 201 Viscoat subjects, but a randomization error (Viscoat (control) subject treated with Vitrax II) resulted in 200 subjects per group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitrax II</title>
          <description>Investigational dispersive viscoelastic</description>
        </group>
        <group group_id="P2">
          <title>Viscoat</title>
          <description>Currently marketed viscoelastic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="199">One subject discontinued due to lens exchange.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Results based on safety population (i.e., the population based on the viscoelastic used). If the randomization scheme had been followed correctly, there would have been 199 Vitrax II subjects and 201 Viscoat subjects, but one subject that should have received Viscoat (control treatment) was treated with Vitrax II, which resulted in 200 per group.</population>
      <group_list>
        <group group_id="B1">
          <title>Vitrax II</title>
          <description>Investigational dispersive viscoelastic</description>
        </group>
        <group group_id="B2">
          <title>Viscoat</title>
          <description>Currently marketed viscoelastic</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="8.88"/>
                    <measurement group_id="B2" value="70.1" spread="8.86"/>
                    <measurement group_id="B3" value="69.03" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Intraocular Pressure Spikes 30 mm Hg or Greater Postoperatively</title>
        <description>Cumulative rate of Intraoperative Pressure (IOP) spikes 30 mm Hg (millimeters of mercury) or greater measured postoperatively through three months.</description>
        <time_frame>3 months postoperative</time_frame>
        <population>Results based on Intent-to-Treat (ITT) population (i.e., population based on the intended randomization scheme, which specified 199 Vitrax II subjects and 201 Viscoat subjects). Study statistical analysis plan specified reporting IOP spikes ≥ 30 mmHg for ITT population, which differs from the safety population used in the Participant Flow.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitrax II</title>
            <description>Vitrax II: Investigational Treatment</description>
          </group>
          <group group_id="O2">
            <title>Viscoat</title>
            <description>Viscoat: Control Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Intraocular Pressure Spikes 30 mm Hg or Greater Postoperatively</title>
          <description>Cumulative rate of Intraoperative Pressure (IOP) spikes 30 mm Hg (millimeters of mercury) or greater measured postoperatively through three months.</description>
          <population>Results based on Intent-to-Treat (ITT) population (i.e., population based on the intended randomization scheme, which specified 199 Vitrax II subjects and 201 Viscoat subjects). Study statistical analysis plan specified reporting IOP spikes ≥ 30 mmHg for ITT population, which differs from the safety population used in the Participant Flow.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="6.97" upper_limit="14.14"/>
                    <measurement group_id="O2" value="7.6" lower_limit="4.49" upper_limit="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Mean Endothelial Cell Count</title>
        <description>mean endothelial cell count (measured by Konan specular microscope) at 3 months</description>
        <time_frame>3 months postoperative</time_frame>
        <population>Results based on Intent-to-Treat (ITT) population (i.e., population based on the intended randomization scheme, which specified 199 Vitrax II subjects and 201 Viscoat subjects). Study statistical analysis plan specified reporting mean endothelial cell count for ITT population, which differs from the safety population used in the Participant Flow.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitrax II</title>
            <description>Vitrax II: Investigational Treatment</description>
          </group>
          <group group_id="O2">
            <title>Viscoat</title>
            <description>Viscoat: Control Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Mean Endothelial Cell Count</title>
          <description>mean endothelial cell count (measured by Konan specular microscope) at 3 months</description>
          <population>Results based on Intent-to-Treat (ITT) population (i.e., population based on the intended randomization scheme, which specified 199 Vitrax II subjects and 201 Viscoat subjects). Study statistical analysis plan specified reporting mean endothelial cell count for ITT population, which differs from the safety population used in the Participant Flow.</population>
          <units>number of endothelial cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2454.3" spread="28.87"/>
                    <measurement group_id="O2" value="2366.3" spread="33.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitrax II</title>
          <description>Investigational dispersive viscoelastic</description>
        </group>
        <group group_id="E2">
          <title>Viscoat</title>
          <description>Currently marketed viscoelastic</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.7</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>IOP Spike greater than or equal to 30 mm HG</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="200"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least ninety (90) days prior to any proposed submission for publication or presentation of Study Data or other findings related to the Study, Institution will provide Sponsor with a manuscript of such submission(s) for review, comment, and approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kendra Hileman, Ph.D., Head, Clinical Research &amp; Development</name_or_title>
      <organization>Abbott Medical Optics, Inc.</organization>
      <phone>714-247-8613</phone>
      <email>kendra.hileman@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

